NASDAQ:EOLS Evolus Q3 2025 Earnings Report $6.14 -0.09 (-1.44%) Closing price 04:00 PM EasternExtended Trading$6.10 -0.04 (-0.65%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileForecast Evolus EPS ResultsActual EPSN/AConsensus EPS -$0.14Beat/MissN/AOne Year Ago EPSN/AEvolus Revenue ResultsActual RevenueN/AExpected Revenue$67.75 millionBeat/MissN/AYoY Revenue GrowthN/AEvolus Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time4:30PM ETConference Call ResourcesCompany Profile Evolus Earnings HeadlinesEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3 hours ago | businesswire.comQuidelOrtho (NASDAQ:QDEL) and Evolus (NASDAQ:EOLS) Financial ComparisonOctober 6, 2025 | americanbankingnews.com7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all flashing red at the same time.October 10 at 2:00 AM | American Alternative (Ad)Analysts Set Evolus, Inc. (NASDAQ:EOLS) Price Target at $21.25October 6, 2025 | americanbankingnews.comTop Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler LaunchSeptember 22, 2025 | prnewswire.comWhile shareholders of Evolus (NASDAQ:EOLS) are in the black over 5 years, those who bought a week ago aren't so fortunateSeptember 20, 2025 | finance.yahoo.comSee More Evolus Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evolus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evolus and other key companies, straight to your email. Email Address About EvolusEvolus (NASDAQ:EOLS) is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients. The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S. Food and Drug Administration in early 2019 for the temporary improvement in the appearance of moderate to severe frown lines. Jeuveau is marketed in the United States through a direct-sales model, supported by a dedicated sales force and a digital ordering platform. Evolus has also secured rights to commercialize Jeuveau in Canada and holds distribution agreements aimed at expanding its reach into select European markets. Since launch, Evolus has invested in physician education and patient-focused support programs, collaborating with dermatologists, plastic surgeons and aesthetic specialists to build awareness of Jeuveau’s clinical profile. The company maintains a manufacturing partnership with a South Korean contract manufacturer, ensuring consistency in product quality and supply chain reliability. Evolus regularly publishes safety and efficacy data from post-marketing studies to reinforce confidence among healthcare providers and patients. Under the leadership of President and Chief Executive Officer Megan Kilcoyne, who joined Evolus in 2019 and was appointed CEO in 2020, the company has expanded its commercial infrastructure and launched new initiatives in digital engagement. Evolus continues to pursue strategic partnerships and potential development candidates that align with its mission to deliver innovative, high-quality aesthetic solutions to markets worldwide.View Evolus ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
